Navigation Links
aTyr Pharma Completes $49 Million Financing to Advance a Therapeutic Pipeline for Rare Autoimmune Diseases from a Newly Discovered Class of Proteins, Physiocrines
Date:7/29/2013

SAN DIEGO, July 29, 2013 /PRNewswire/ -- aTyr Pharma, an innovative protein therapeutics enterprise focused on rare diseases, announced today the successful completion of a $49 million financing. A premier, global public investment fund joined existing investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners in the equity financing. The financing supports the clinical development of aTyr's first therapeutic program to treat rare autoimmune diseases and a rare disease pipeline in immune disorders.  The financing had robust demand, and the private stock placement was capped at $49 million by the company. 

(Logo: http://photos.prnewswire.com/prnh/20120809/MM55538LOGO)

"Our focus on new biology in immunology rapidly translated into development of protein therapeutics to treat essentially untreatable, grave immune disorders.  Our existing and new investors recognized the promise in a new class of proteins, Physiocrines, to treat many different types of disease with proteins made by the human body to orchestrate our immune system," said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. "Our emerging pipeline in immunomodulation represents an industry unique opportunity to therapeutically intervene via the basic mechanisms of innate and adaptive immunity in a way never enabled before. The aTyr team believes these mechanisms will benefit patients with grave outcomes in ways that antibody and small molecule approaches can not because Physiocrines evolved to naturally balance the immune system to resolve inflammation rather than being a designed inhibitor of pro-inflammatory pathways."

About Physiocrines

Physiocrines act as extracellular signaling molecules to orchestrate cellular homeostasis in response to stress. Physiocrines are naturally occurring proteins derived from tRNA synthetases that play fundamental roles in the function of human physiology and the resolution of inflammation. As potent endogenous modulators of inflammation, Physiocrines offer the opportunity for modulating biological pathways through new naturally occurring mechanisms, many of which have multiple therapeutic advantages, including improved selectivity, efficacy and reduced side effect profiles compared to many existing anti-inflammatory therapeutics.

About aTyr Pharma

aTyr Therapeutics plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. aTyr has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr's key programs are currently focused on rare immunomodulation disorders in the areas of inflammation and auto-immunity. These diseases are serious potentially life threatening autoimmune conditions, for which there are currently no effective, safe, long-term treatments. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Partners. For more information, please visit http://www.atyrpharma.com.


'/>"/>
SOURCE aTyr Pharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
6. Academy of Managed Care Pharmacy (AMCP) Installs 2012-2013 Board of Directors
7. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
8. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
9. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
10. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
11. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... , June 30, 2017  AVACEN Medical (AVACEN) announced the publication ... research describes the use of its AVACEN Treatment Method ... from fibromyalgia. ... AVACEN Medical ... by chronic widespread pain. It affects approximately 200 to 400 million people ...
(Date:6/27/2017)...  Therapix Biosciences Ltd. (Nasdaq: TRPX ) ... development of cannabinoid-based drugs, today announced that the Company ... New York, NY on Wednesday, ... offering (IPO) of American Depository Shares (ADSs) listed on ... Dr. Elran Haber, Ph.D., Chief Executive Officer of Therapix, ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Right now, behind ... The agency is hammering out a game plan to implement changes and compromises ... to affect FDA-regulated firms. The new law:, ,     Seeks ways ...
(Date:7/24/2017)... ... 2017 , ... “A Short Walk to the Mailbox”: a remarkable memoir of ... published author, Ed Clark. Ed Clark is a church music director and choral ... minister of music and worship leader for over fifty years. He has a ...
(Date:7/23/2017)... , ... July 23, 2017 , ... A 20-year-long ... St. Louis, and led by the Minneapolis Veterans Administration Health Care System overwhelmingly supports ... the disease offers very few benefits. , In the cases involved with this ...
(Date:7/23/2017)... ... July 23, 2017 , ... “I Am Not Nothin’: The Serpent ... who could barely read and write and a brokenhearted young soldier who turned to ... of age novel about the power of simple faith is the work of published ...
(Date:7/22/2017)... TORONTO, ONTARIO, CANADA (PRWEB) , ... July 22, ... ... surgeries take place each year with the majority of patients not requiring pain ... American Orthopaedic Society for Sports Medicine’s Annual Meeting today in Toronto, Ontario, ...
Breaking Medicine News(10 mins):